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Mitral  valve  repair  (MVR)  remains  the  gold  standard  [1]  treatment  for  mitral  valve  regur-
gitation,  with  excellent  results  for  dystrophic  disease.  Nevertheless,  the  most  recent
adaptations  concern  the  treatment  of  ischaemic  or  functional  mitral  regurgitation  and
the  development  of  less  invasive  approaches.  The  availability  of  video-assisted  surgeries
or  percutaneous  approaches  is  therefore  the  subject  of  growing  interest  [2].
Less invasive resection
One  of  the  most  frequently  used  procedures  for  MVR  has  been  the  more  or  less  extended
tissue  resection  (in  particular,  P2  quadrangular  resection).  Today,  the  trend  is  to  resect
less  tissue,  perform  triangular  resection,  repair  without  any  resection  [3],  or  use  Goretex
neochordae  [4].  One  original  yet  unorthodox  technique  —  the  Alﬁeri  stitch  creating  a  double
oriﬁce  mitral  valve  —  gave  surprising  and  long-lasting  results  [5].  This  technique  even  had
speciﬁc  value  in  functional  mitral  regurgitation,  where  the  recurrence  of  regurgitation  was
less  frequent  when  an  Alﬁeri  stitch  was  added  compared  with  single  annuloplasty  [6].
Less invasive surgical approachAll  surgical  specialities  have  developed  minimally  invasive  techniques  using  videoscopy
(e.g.  cholecystectomy,  menisectomy,  surgery  for  pneumothorax,  thoracic  sympa-
thectomy).  In  cardiac  surgery,  one  meta-analysis  reported  results  from  more  than
14,000  patients  [7].  The  conclusion  was  that  minimally  invasive  surgery  may  be  an
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lternative  to  conventional  mitral  valve  surgery,  with  similar
ates  of  mortality  and  morbidity  (renal,  pulmonary,  cardiac
omplications,  pain  perception,  and  readmissions),  reduced
ternal  complications,  transfusions,  postoperative  atrial  ﬁb-
illation,  duration  of  ventilation,  and  intensive  care  unit
nd  hospital  length  of  stay.  However,  this  should  be  bal-
nced  against  the  increased  risk  of  stroke,  aortic  dissection,
hrenic  nerve  palsy  and  groin  infections  or  complications.
hese  complications  (mainly  in  the  endoclamp  group)  could
e  avoided.  As  a  consequence,  the  minimally  invasive
pproach  with  a  transthoracic  aortic  clamp  can  maintain
he  beneﬁt  with  a  lower  risk  of  complications.  This  surgery
as  become  routine  in  reference  centres;  moreover,  it  is  a
tepping-stone  to  future  beating  heart  valve  repairs.  Beat-
ng  heart  valve  surgery  merges  the  advantages  of  open  heart
urgery  with  the  transesophageal  echocardiogram  (TEE)-
uided  approach  used  during  endovascular  procedures:
mage  guidance  allows  monitoring  during  the  procedures  to
uide  the  intervention  according  to  the  dysfunction  rather
han  to  the  anatomical  lesion,  taking  advantage  of  the  phys-
ological  conditions;  this  is  in  contrast  to  the  conventional
urgical  approach,  which  is  performed  under  cardioplegic
rrest.  A  good  example  of  the  advantage  of  beating  heart
pproach  is  neochordal  implant:
transapical  implantation  of  neochordae  has  been
described  with  different  technologies  (left  mini-
thoracotomy):  NeoChord  Inc.  (Minnetonka,  USA)  is  devel-
oping  a  transapical  device  that  allows  the  correction  of  a
prolapsed  leaﬂet.  Animal  studies  and  even  a  ‘ﬁrst  in  man’
trial  have  been  published  [8],  with  encouraging  results;
trans  left  atrial  approach  (right  mini-thoracotomy):
Valtech  Cardio  (Or  Yehuda,  Israel)  is  developing  an
adjustable  length  neochordae  device,  which  is  implanted
with  a  sutureless  approach  into  the  tip  of  the  papillary
muscle  and  then  attached  to  the  free  edge  of  the  leaﬂet.
Afterwards,  the  length  is  adjusted  under  TEE  on  a  beating
heart.
ess invasive percutaneous approach
o  be  effective  percutaneous  techniques  have  to  respect  the
ules  of  surgical  repair.  The  success  of  percutaneous  mitral
ommissurotomy  was  mainly  due  to  the  fact  that  balloon
nﬂation  faithfully  reproduced  the  original  surgical  commis-
urotomy.  Mitral  valve  repair  is  much  more  complex  and
herefore  not  so  easy  to  reproduce.  Percutaneous  mitral
alve  repair  includes  three  main  technological  categories:
oronary  sinus  indirect  annuloplasty,  direct  annuloplasty  and
irect  leaﬂets  correction.
oronary sinus indirect annuloplasty
oronary  sinus  indirect  annuloplasty  consists  of  inserting  a
evice  into  the  coronary  sinus  to  modify  the  mitral  annulus.
lthough  it  is  intrinsically  easy  to  perform,  this  approach  has
everal  limitations.  The  annuloplasty  is  only  partial,  with  a
isk  of  compressing  the  circumﬂex  artery  in  up  to  6%  of  cases
nd  a  risk  of  tamponade  in  3—6%.  To  date,  three  devices  have
een  tested  in  humans:
MONARCTM  device  (Edwards  Lifesciences  Inc.):  72
patients  treated  [9];
M
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CARILLONTM  Mitral  Contour  System  (Cardiac  Dimensions
Inc.):  48  patients  treated  [10];
Viacor  PTMA© (PTMA  Viacor  Inc.):  27  patients  treated  [11].
Thirty-day  death  rates  are  low,  between  0%  and  2%,  but
fﬁcacy  has  been  evaluated  in  only  small  non-randomized
eries  using  surrogate  endpoints.  Within  the  ﬁrst  year,  the
ffective  regurgitant  oriﬁce  area  decreased  by  approxi-
ately  30%  and  the  regurgitant  volume  by  20—25%.  The
esponse  was  heterogeneous  and  certain  patients  expe-
ienced  more  marked  reduction  of  mitral  regurgitation.
he  future  of  coronary  sinus  annuloplasty  is  compro-
ised,  although  efﬁcacy  has  been  demonstrated  in  selected
atients.
irect annuloplasty
irect  annuloplasty  more  closely  resembles  surgical  annu-
oplasty.  These  technologies  are  at  an  early  phase  of
evelopment.  The  Mitralign  Percutaneous  Annuloplasty  Sys-
em  (Mitralign,  Tewksbury,  MA,  USA)  is  a device  used  to
erform  selective  plications  of  the  annulus  with  a  retro-
rade  approach  (from  the  left  ventricle)  via  a  transfemoral
rterial  access  site.  A  couple  of  plications  are  obtained  to
educe  annular  dimensions,  by  means  of  pledgetted  anchors
enetrating  the  base  of  the  leaﬂets.  Guided  Delivery  Sys-
ems  (Santa  Clara,  CA,  USA)  is  developing  a  cinching  device
Accucinch)  consisting  of  multiple  anchors  implanted  suban-
ularly  below  the  leaﬂets,  from  commissure  to  commissure,
nd  joined  by  a  contracting  wire.  A  ﬂexible  ring  ‘Cardioband’
ntroduced  through  a  right  mini-thoracotomy  and  through
he  left  atrium  can  be  screwed  into  the  mitral  annulus  under
EE.  Preclinical  development  has  been  completed  and  early
uman  experience  is  ongoing.
irect leaﬂets correction
resent  techniques  are  far  from  meeting  the  complexity
nd  variability  of  diverse  anatomical  situations  of  mitral
alve  disease  and  the  corresponding  spectrum  of  surgical
echniques  of  valve  repair.  The  only  current  solid  project
MitraClip  Inc.,  Abbott  Vascular;  CE  mark  in  2008)  repro-
uces  the  ‘Alﬁeri  stitch’  by  ﬁxing  the  two  leaﬂets  with  a
lip  introduced  through  a  venous  transfemoral  and  transsep-
al  approach.  However,  this  percutaneous  approach  does
ot  exactly  reproduce  Alﬁeri’s  rules,  since  Alﬁeri  himself
ighlighted  the  necessity  to  add  an  annuloplasty  to  obtain
urable  results.
The  Endovascular  Valve  Edge-to-Edge  Repair  Study  (EVER-
ST  II)  [12]  randomized  279  patients  with  severe  mitral
egurgitation  in  37  centres  to  MitraClip  (n  =  184)  or  surgi-
al  valve  repair  or  replacement  (n  =  95).  Mitral  regurgitation
as  of  organic  origin  in  73%  of  the  cases.  At  12  months,
he  rates  of  the  primary  outcome  for  efﬁcacy  were  55%  in
he  percutaneous-repair  group  and  73%  in  the  surgery  group
p  =  0.007).  The  respective  rates  of  the  components  of  the
rimary  outcome  were  as  follows:  death,  6%  in  each  group;
urgery  for  mitral  valve  dysfunction,  20%  vs  2%,  respectively.
ajor  adverse  events  (mainly  blood  transfusions)  occurred
n  15%  of  patients  in  the  percutaneous-repair  group  and  in
8%  of  patients  in  the  surgery  group  at  30  days  (p  < 0.001).
t  12  months,  both  groups  had  improved  left  ventricular
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size,  New  York  Heart  Association  (NYHA)  functional  class,
and  quality-of-life  measures,  compared  with  baseline.  In
summary,  percutaneous  repair  was  less  effective  at  redu-
cing  mitral  regurgitation  than  conventional  surgery,  but  the
procedure  was  associated  with  superior  safety  (mainly  fewer
blood  transfusions)  and  similar  improvements  in  clinical  out-
comes  at  1  year.
In a  study  related  to  EVEREST  II  (High-Risk  Registry)  in
individuals  ineligible  for  randomization,  78  patients  were
treated  with  a  Mitraclip,  and  their  results  were  compared
with  those  of  a  control  group  of  38  patients  treated
with  optimal  medical  medication.  This  observational  study
showed  a  higher  survival  rate  in  the  Mitraclip  group  (76%  vs
55%  at  1  year).
Today,  ACCESS-EU  — a  European  multicentre,  post-
approval  registry  —  reported  on  566  patients  with  mean  age
of  74  ±  10  years,  procedure  time  of  117  minutes,  and  length
of  hospital  stay  of  7.7  days.  The  rate  of  hospital  death  was
2%  and  6-month  survival  89%,  with  no  embolizations;  the
rate  of  mitral  regurgitation  was  less  than  2  at  6  months  was
80%,  and  patients  showed  improved  NYHA  functional  class,
quality  of  life  and  6-minute  walk  distance  [13].
In the  MitraClip  experience  (>  5000  patients  implanted
worldwide,  particularly  in  northern  Europe  and  Italy),  pro-
cedural  success  rates  are  high  and  severe  procedure-related
complications  rare.  Feasibility  does  not,  however,  imply  efﬁ-
cacy,  and  it  is  too  early  to  ascertain  the  clinical  utility  of
these  techniques.  The  effect  on  NYHA  class  is  a  relevant
outcome  but  its  assessment  may  be  subjective.
Given  the  low  operative  risk  and  the  excellent
immediate-  and  long-term  results  of  valve  repair  for  valve
prolapse,  it  is  unlikely  that  the  MitraClip  will  replace  surgery
in  the  near  future.  Nevertheless,  percutaneous  techniques
could  be  an  option  in  patients  with  degenerative  mitral
regurgitation  who  are  at  high  surgical  risk  because  of
advanced  age  and  presence  of  comorbid  conditions  [14].
With  regard  to  functional  or  ischaemic  mitral  regurgitation,
the  situation  is  more  difﬁcult,  since,  unlike  in  organic  mitral
regurgitation,  surgery  is  not  a  reference  treatment  [15].
Consequently,  in  Europe  today,  functional  mitral  regurgita-
tion  comprises  close  to  80%  of  the  indications,  highlighting
the  need  for  speciﬁc  randomized  trials  assessing  the  clini-
cal  beneﬁt  of  the  MitraClip  in  functional  or  ischaemic  mitral
regurgitation.
In  conclusion,  less  invasive  procedures  are  progressing
in  every  medical  domain,  with  new  techniques  that  are  in-
between  traditional  surgery  and  percutaneous  approaches.
Minimally  invasive  mitral  valve  surgery  is  now  validated,
with  improved  results,  provided  it  is  performed  in  an  expe-
rienced  centre.  Moreover,  this  procedure  is  a  ﬁrst  step
for  future  less  invasive  techniques  such  as  transapical
approaches.
In  contrast  to  surgical  mitral  valve  repair,  which  is  a
mature  procedure,  percutaneous  procedure  results  (mainly
with  the  MitraClip)  should  improve  over  time.  Although
some  procedures  (e.g.  neochordae  implantation,  adjustable
annuloplasty  band)  are  in  their  infancy,  it  is  likely  that  per-
cutaneous  treatments  will  play  a  part  in  the  treatment  of
mitral  regurgitation.  Beyond  early  feasibility  studies,  ran-
domized  trials  are  now  mandatory  in  order  to  conﬁrm  these
promising  results.eous  approach  403
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